handling the sample traffic cars. Train mile unit costs should also reflect the trailing weight of the trains handling the sample traffic cars.

Marine-operation costs shall be excluded from computation of the unit costs and applied on a direct basis including appropriate departmental and general overheads.

Revenue Need Evidence. Each railroad or group of railroads which participates in the joint rates or fares should submit evidence of system revenue needs. For this purpose, the following specific data and information, combined where appropriate into applicable carrier groupings, shall be submitted:

(1) Selected financial data of the kind prescribed for the Schedule A filings, as prescribed and defined in Ex Parte No. 290, *Procedures Governing Rail General Increase Proceedings* (351 ICC 619 and 620).

(2) Income and sum of money data of the kind prescribed and defined for Schedule B (Part I, column (a) through (c) only) in Ex Parte No. 290, supra.

For the purposes of compiling these data "base year—actual" shall be the same annual period utilized in developing the traffic and cost study data suggested herein. If relevant, the carriers may, at their option, provide in addition to these data cost of capital studies or any other evidence having a direct bearing on their revenue needs to earn a fair return on rail property held for and used in the service of transportation. Also, in instances where the system revenue needs of the opposing parties are markedly different, the carriers may wish to allocate a portion of such overall revenue need to the traffic at issue. In such cases, the allocation scheme employed should be fully explained, and where necessary, supported by a detailed, independent study of the revenue contributions to system revenues generated by the issue traffic. In instances where passenger and/or commuter operations are subsidized, such facts and attendant circumstances should be fully disclosed, including a detailed accounting of the subsidies relative to total revenue.

[FR Doc. 76-11200 Filed 4-16-76;8:45 am]

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[21 CFR Part 1308]

DEXTRORPHAN

Removal From Schedule I of Schedules of Controlled Substances

Dextrorphan is a controlled substance listed in Schedule I of the Comprehensive Drug Abuse Prevention and Control Act of 1970 [21 U.S.C. 812(c) Schedule I.(a)(13); § 1308.11(b)(13), Title 21 of the Code of Federal Regulations (CFR)].

On November 14, 1974, the Drug Enforcement Administration received a petition for the initiation of proceedings to remove dextrorphan from control under the Act. The petitioner is Hoffman-La-Roche, Inc.

By a letter dated November 20, 1974, the Drug Enforcement Administration notified Hoffman-LaRoche, Inc., that the above petition has been accepted for filing in accordance with 21 CFR § 1308.-44(c). Notice of acceptance for filing of this petition was published in the FEDERAL REGISTER, Vol. 39, No. 237, Monday, December 9, 1974.

The Drug Enforcement Administration has reviewed and evaluated the petition in order to determine whether the grounds upon which the petitioner relies are sufficient to justify the initiation of the requested proceedings.

Based upon the investigations of the Drug Enforcement Administration and upon the scientific and medical evaluation and recommendation of the Secretary of Health, Education, and Welfare, received pursuant to Section 201(b) of the Act (21 U.S.C. 811(b)), the Administrator of the Drug Enforcement Administration finds that dextrorphan does not have sufficient potential for abuse or abuse liability to justify its continued control in any schedule under the Act.

Therefore, under the authority vested in the Attorney General by Section 201 (a) of the Act (21 U.S.C. 811(a)), and delegated to the Administrator of the Drug Enforcement Administration by regulations of the Department of Justice (28 CFR Part O), the Administrator hereby proposes that CFR 1308.11(b) be amended as follows:

§ 1308.11 Schedule I.

* * * * *

(b) Opiates—Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation:

(1)	Acetylmethadol	9601
(2)	Allylprodine	9602
(3)	Alphacetylmethadol	9603
(4)	Alphameprodine	9604
(5)	Alphamethadol	9605
(6)	Benzethidine	9606
(7)	Betacetylmethadol	9607
(8)	Betameprodine	9608
(9)	Betamethadol	9609
(10)	Betaprodine	9611
(11)	Clonitazene	9612
(12)	Dextromoramide	9613
(13)	Diampromide	9615
(14)	Diethylthiambutene	9616
(15)	Dimenoxadol	9617
(16)	Dimepheptanol	9618
(17)	Dimethylthiambutene	9619
(18)	Dioxaphetyl butyrate	9621
(19)	Dipipanone	9622
(20)	Ethylmethylthiambutene	9623
(21)	Etonitazene	9624
(22)	Etoxeridine	9625
(23)	Furethidine	9626
(24)	Hydroxypethidine	9627
(25)	Ketobemidone	9628
(26)	Levomoramide	9629
(27)	Levophenacylmorphan	9631
(28)	Morpheridine	9632
(29)	Noracymethadol	9633
(30)	Norlevorphanol	9634
(31)	Normethadone	9635
(32)	Norpipanone	9636
(33)	Phenadoxone	9637
(34)	Phenampromide	9638
(35)	Phenomorphan	9647
(36)	Phenoperidine	9641
(37)	Piritramide	9642
(38)	Proheptazine	9643
(39)	Properidine	9644
(40)	Propiram	9649
(41)	Racemoramide	9645
(42)	Trimeperidine	9646

* * * * *

All interested persons are invited to submit their comments or objections in writing regarding this proposal. These comments or objections should state with particularity the issues concerning which the person desires to be heard. Comments and objections should be submitted in quintuplicate to the Administrator, Drug Enforcement Administration, United States Department of Justice, 1405 Eye Street, N.W., Washington, D.C. 20537, Attention: DEA Federal Register Representative, and must be received on or before May 25, 1976.

In the event that an interested party submits objections to this proposal which present reasonable grounds for this rule not to be finalized and requests a hearing in accordance with 21 CFR 1308.45, the party will be notified by registered mail of the time and place that the hearing will be held. If objections submitted do not present such reasonable grounds, the party will be so advised by registered mail.

If no objections presenting grounds for a hearing on the proposal are received within the time limitations, or all interested parties waive or are deemed to waive their opportunity for a hearing or to participate in a hearing, the Administrator, after giving considerations to written comments and objections, will issue his final order pursuant to 21 CFR 1308.48 without a hearing.

Dated: April 8, 1976.

JERRY N. JENSON,
Deputy Administrator,
Drug Enforcement Administration.

[FR Doc.76-11249 Filed 4-16-76;8:45 am]

[21 CFR Part 1311]

CONTROLLED SUBSTANCES

Registration of Importers and Exporters; Correction

In FR Doc. 76-9664 appearing at page 14399 in the FEDERAL REGISTER of April 5, 1976, paragraph (f) of § 1311.42 appearing on page 14400 is corrected in the tenth line of that paragraph by adding the number, "(6)", immediately following the letter "(c)", and immediately before the number, "(ii)".

The time period for filing comments, objections and requests for hearing is extended to May 25, 1976.

Dated: April 13, 1976.

PETER B. BENSINGER,
Administrator,
Drug Enforcement Administration.

[FR Doc.76-11248 Filed 4-16-76;8:45 am]